The Cancer News

Entries

• Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
  October 30, 2026

  Learn how centers manage cytokine release syndrome after CAR-T and bispecific therapy, from outpatient monitoring to ...

• Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
  October 29, 2026

  Learn how prior authorization and specialty pharmacy steering delay oral chemotherapy, add financial toxicity, and ho...

• The Post–CAR-T Playbook: What Comes Next?
  October 28, 2026

  Learn how timing of relapse shapes post-CAR-T treatment in large B-cell lymphoma, from CD20 bispecific combinations t...

• The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
  October 22, 2026

  See how CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates are reshaping treatment sequencing fo...

• Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
  October 21, 2026

  Explore the expanding oral SERD landscape and how ctDNA-guided treatment switching before progression is changing HR-...

• Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
  October 17, 2026

  Learn the structured monitoring schedule for capivasertib-associated hyperglycemia and when home glucometer use can h...

• A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
  October 17, 2026

  Learn how weight-based dose rounding in antibody-drug conjugate therapy can silently double an intended dose change, ...

• A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
  October 15, 2026

  Explore pleomorphic dermal sarcoma updates: UV-driven high TMB, pembrolizumab efficacy, differential diagnosis, and o...

• Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
  October 13, 2026

  Explore peripheral T-cell lymphoma subtyping updates: expert pathology discordance, HTLV-1 testing, CD30 thresholds, ...

• PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
  October 10, 2026

  Explore immunotherapy biomarker updates: PD-L1 limits, TMB CheckMate 227 trials, HLA and ctDNA models, and prospectiv...

• Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
  October 09, 2026

  Explore muscle-invasive bladder cancer updates: perioperative EV-Pembro approval, KEYNOTE-B15 data, and IMvigor011 ct...

• Surgery or Radiation for Stage III Lung Cancer? The Better Question Is Not Which, But When Do We Decide
  October 07, 2026

  Explore Stage III NSCLC updates: PACIFIC durvalumab data, neoadjuvant chemo-immunotherapy conversion rates, and multi...

• ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
  October 07, 2026

  Explore ER+ breast cancer updates: lidERA giredestrant data, vepdegestrant PROTAC approvals, and SERENA-6 ctDNA-guide...

• A Rare Liver Cancer in a Young Woman Underscores the Need for More Options
  October 07, 2026

  Explore fibrolamellar carcinoma updates: DNAJB1-PRKACA fusion insights, STRIDE regimen challenges, and gemcitabine-ox...

• Targeting Endocrine Resistance: New Sequencing Strategies in Metastatic Breast Cancer
  October 05, 2026

  Explore metastatic breast cancer updates: ESR1 oral SERDs, vepdegestrant PROTAC data, PI3K/AKT inhibitors, and ctDNA-...

• Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
  October 05, 2026

  Explore liver cancer updates: EMERALD-3 TACE plus STRIDE data, TARE practice patterns, and GLP-1 receptor agonist sig...

• Advances in the Management of Lung Cancer in 2025 and 2026
  October 01, 2026

  Explore key advances in SCLC and NSCLC management, including drug approvals, bispecific T-cell engagers, antibody-dru...

• Leptomeningeal Disease Is Becoming More Common, and Also More Treatable
  September 30, 2026

  Explore leptomeningeal disease updates: EGFR/ALK targeted therapies, NCCN CSF ctDNA testing guidelines, and proton cr...

• Sequencing CAR-T and Bispecific Antibodies in Multiple Myeloma: What the Data Show
  September 28, 2026

  Explore multiple myeloma updates: CAR-T vs. bispecific sequencing, T-cell exhaustion factors, IVIG infection prophyla...

• At-Home Cervical Cancer Screening Kits Outperform Office-Based Approach in Under-Resourced Settings
  September 21, 2026

  New research from MD Anderson finds mailed HPV screening kits more effective than clinic-based exams, offering a game...